Skip to main content
. 2019 Jul 19;68(2):1–33. doi: 10.15585/mmwr.rr6802a1

TABLE 4. Seroprotection rates and geometric mean titers among adults at intervals after first dose of a 2-dose primary series of inactivated Vero cell culture–derived Japanese encephalitis vaccine, by tickborne encephalitis vaccination status.

Measure 6 mos
12 mos
24 mos
60 mos
Seroprotection rate*
Total
No. seroprotected
(%)
Total
No. seroprotected
(%)
Total
No. seroprotected
(%)
Total
No. seroprotected
(%)
TBE vaccine
89
86
(97)
89
82
(92)§
86
78
(91)§
78
67
(86)§
No TBE vaccine
92
86
(93)
92
69
(75)
78
53
(68)
47
30
(64)
GMT
GMT
GMT
GMT
GMT
TBE vaccine
96
48
56
45
No TBE vaccine 73
35
33
29

Sources: Dubischar-Kastner K. New clinical data for IXIARO Japanese encephalitis vaccine, inactivated, adsorbed. Presentation to Advisory Committee on Immunization Practices (ACIP), February 24, 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. https://stacks.cdc.gov/view/cdc/60592; Taucher C, Kollaritsch H, Dubischar KL. Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study. Vaccine 2019;37:2529–31.

Abbreviations: GMT = geometric mean titer; TBE = tickborne encephalitis.

* Proportion with 50% plaque reduction neutralization test titer ≥10.

TBE vaccine received before or after Vero cell culture–derived Japanese encephalitis vaccine.

§ Nonoverlapping 95% confidence intervals (calculated according to the method recommended by Altman, developed by Wilson) for seroprotection rates for TBE and no TBE vaccine groups.